Table of Contents GBI Research Report Guidance 2 Executive Summary 3 Table of Contents 4 List of Tables 6 List of Figures 13 Introduction 15 GBI Research Report Coverage 15 Acne Vulgaris Overview 15 Psoriasis Overview 15 Atopic Dermatitis Overview 15 Therapeutics Development 16 Acne Vulgaris 16 Psoriasis 18 Atopic Dermatitis 20 Therapeutics under Development by Companies 22 Acne Vulgaris 22 Psoriasis 24 Atopic Dermatitis 31 Therapeutics under Investigation by Universities/Institutes 34 Acne Vulgaris 34 Psoriasis 35 Atopic Dermatitis 36 Pipeline Products Glance 37 Acne Vulgaris 37 Psoriasis 40 Atopic Dermatitis 44 Products under Development by Companies 47 Acne Vulgaris 47 Psoriasis 49 Atopic Dermatitis 58 Products under Investigation by Universities/Institutes 62 Acne Vulgaris 62 Psoriasis 62 Atopic Dermatitis 63 Companies Involved in Therapeutics Development 64 Acne Vulgaris 64 Psoriasis 95 Atopic Dermatitis 245 Therapeutics Assessment 323 Acne Vulgaris 323 Psoriasis 335 Atopic Dermatitis 363 Dormant Projects 377 Acne Vulgaris 377 Psoriasis 380 Atopic Dermatitis 389 Discontinued Products 392 Acne Vulgaris 392 Psoriasis 392 Atopic Dermatitis 395 Product Development Milestones 396 Acne Vulgaris 396 Psoriasis 408 Atopic Dermatitis 420 Appendix 431 Methodology 431 Coverage 431 Secondary Research 431 Primary Research 431 Expert Panel Validation 431 Contact Us 431 Disclaimer 432

List of Tables Number of Products under Development for Acne Vulgaris, 16 Number of Products under Development for Acne Vulgaris – Comparative Analysis, 17 Number of Products under Development for Psoriasis, 18 Number of Products under Development for Psoriasis – Comparative Analysis, 19 Number of Products under Development for Atopic Dermatitis, 20 Number of Products under Development for Atopic Dermatitis – Comparative Analysis, 21 Number of Products under Development by Companies 22 Number of Products under Development by Companies 25 Number of Products under Development by Companies 31 Number of Products under Investigation by Universities/Institutes, 34 Number of Products under Investigation by Universities/Institutes, 34 Number of Products under Investigation by Universities/Institutes, 35 Number of Products under Investigation by Universities/Institutes, 36 Comparative Analysis by Late Stage Development, 37 Comparative Analysis by Clinical Stage Development, 38 Comparative Analysis by Early Stage Development, 39 Comparative Analysis by Late Stage Development, 40 Comparative Analysis by Clinical Stage Development, 41 Comparative Analysis by Early Stage Development, 42 Comparative Analysis by Unknown Stage Development, 43 Comparative Analysis by Late Stage Development, 44 Comparative Analysis by Clinical Stage Development, 45 Comparative Analysis by Early Stage Development, 46 Products under Development by Companies 47 Products under Development by Companies 49 Products under Development by Companies, 58 Products under Investigation by Universities/Institutes, 62 Products under Investigation by Universities/Institutes, 62 Products under Investigation by Universities/Institutes, 63 Acne Vulgaris – Pipeline by 3SBio Inc, 64 Acne Vulgaris – Pipeline by Allergan Plc, 64 Acne Vulgaris – Pipeline by Almirall SA, 65 Acne Vulgaris – Pipeline by Antibiotx ApS, 65 Acne Vulgaris – Pipeline by Biomar Microbial Technologies, 66 Acne Vulgaris – Pipeline by BioPharmX Inc, 66 Acne Vulgaris – Pipeline by Braintree Laboratories Inc, 67 Acne Vulgaris – Pipeline by Brickell Biotech Inc, 67 Acne Vulgaris – Pipeline by Cell Medica Ltd, 68 Acne Vulgaris – Pipeline by Cellceutix Corp, 68 Acne Vulgaris – Pipeline by Celtaxsys Inc, 69 Acne Vulgaris – Pipeline by Common Pharma Inc, 69 Acne Vulgaris – Pipeline by Cutanea Life Sciences Inc, 70 Acne Vulgaris – Pipeline by DermaXon LLC, 70 Acne Vulgaris – Pipeline by Dermira Inc, 71 Acne Vulgaris – Pipeline by ELORAC Inc, 71 Acne Vulgaris – Pipeline by Ensol Biosciences Inc, 72 Acne Vulgaris – Pipeline by Foamix Pharmaceuticals Ltd, 72 Acne Vulgaris – Pipeline by Galderma SA, 73 Acne Vulgaris – Pipeline by GlaxoSmithKline Plc, 73 Acne Vulgaris – Pipeline by Helix BioMedix Inc, 74 Acne Vulgaris – Pipeline by Hovione FarmaCiencia SA, 74 Acne Vulgaris – Pipeline by Lee's Pharmaceutical Holdings Ltd, 75 Acne Vulgaris – Pipeline by LEO Pharma A/S, 76 Acne Vulgaris – Pipeline by Novabiotics Ltd, 77 Acne Vulgaris – Pipeline by Novan Inc, 78 Acne Vulgaris – Pipeline by Paratek Pharmaceuticals Inc, 79 Acne Vulgaris – Pipeline by Pfizer Inc, 80 Acne Vulgaris – Pipeline by Phosphagenics Ltd, 81 Acne Vulgaris – Pipeline by Photocure ASA, 82 Acne Vulgaris – Pipeline by Promius Pharma LLC, 83 Acne Vulgaris – Pipeline by Provectus Biopharmaceuticals Inc, 84 Acne Vulgaris – Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, 85 Acne Vulgaris – Pipeline by Sol-Gel Technologies Ltd, 86 Acne Vulgaris – Pipeline by Sun Pharma Advanced Research Company Ltd, 87 Acne Vulgaris – Pipeline by Telesso Technologies Ltd, 88 Acne Vulgaris – Pipeline by Thesan Pharmaceuticals Inc, 89 Acne Vulgaris – Pipeline by Valeant Pharmaceuticals International Inc, 90 Acne Vulgaris – Pipeline by Vectura Group Plc, 91 Acne Vulgaris – Pipeline by Vyome Biosciences Pvt Ltd, 92 Acne Vulgaris – Pipeline by XBiotech Inc, 93 Acne Vulgaris – Pipeline by Xenon Pharmaceuticals Inc, 94 Psoriasis – Pipeline by AbbVie Inc, 95 Psoriasis – Pipeline by Abeome Corp, 96 Psoriasis – Pipeline by AbGenomics International Inc, 97 Psoriasis – Pipeline by Addex Therapeutics Ltd, 98 Psoriasis – Pipeline by Adello Biologics LLC, 99 Psoriasis – Pipeline by Advinus Therapeutics Ltd, 100 Psoriasis – Pipeline by Affibody AB, 101 Psoriasis – Pipeline by Albireo Pharma Inc, 102 Psoriasis – Pipeline by Alfacyte Ltd, 103 Psoriasis – Pipeline by Almirall SA, 104 Psoriasis – Pipeline by Alteogen Inc, 105 Psoriasis – Pipeline by Amgen Inc, 106 Psoriasis – Pipeline by Anacor Pharmaceuticals Inc, 107 Psoriasis – Pipeline by AnaptysBio Inc, 108 Psoriasis – Pipeline by ApoPharma Inc, 109 Psoriasis – Pipeline by Arena Pharmaceuticals Inc, 110 Psoriasis – Pipeline by Argos Therapeutics Inc, 111 Psoriasis – Pipeline by Arrien Pharmaceuticals LLC, 112 Psoriasis – Pipeline by AstraZeneca Plc, 113 Psoriasis – Pipeline by Athenex Inc, 114 Psoriasis – Pipeline by Atlantic Bio Sci LLC, 115 Psoriasis – Pipeline by Aurigene Discovery Technologies Ltd, 116 Psoriasis – Pipeline by Aurinia Pharmaceuticals Inc, 117 Psoriasis – Pipeline by Avexxin AS, 118 Psoriasis – Pipeline by Bayer AG, 119 Psoriasis – Pipeline by Betta Pharmaceuticals Co Ltd, 120 Psoriasis – Pipeline by BioApex sro, 121 Psoriasis – Pipeline by Biocad, 122 Psoriasis – Pipeline by Biocon Ltd, 123 Psoriasis – Pipeline by BioLingus AG, 124 Psoriasis – Pipeline by BioMAS Ltd, 125 Psoriasis – Pipeline by Biomics Biotechnologies Co Ltd, 126 Psoriasis – Pipeline by Bionomics Ltd, 127 Psoriasis – Pipeline by Bionovis SA, 128 Psoriasis – Pipeline by BirchBioMed Inc, 129 Psoriasis – Pipeline by Boehringer Ingelheim GmbH, 130 Psoriasis – Pipeline by Brickell Biotech Inc, 131 Psoriasis – Pipeline by Bristol-Myers Squibb Company, 132 Psoriasis – Pipeline by C4X Discovery Holdings PLC, 133 Psoriasis – Pipeline by CalciMedica Inc, 134 Psoriasis – Pipeline by Can-Fite BioPharma Ltd, 135 Psoriasis – Pipeline by Celgene Corp, 136 Psoriasis – Pipeline by Cell Medica Ltd, 137 Psoriasis – Pipeline by Cellceutix Corp, 138 Psoriasis – Pipeline by ChemoCentryx Inc, 139 Psoriasis – Pipeline by Chipscreen Biosciences Ltd, 140 Psoriasis – Pipeline by ChironWells GmbH, 141 Psoriasis – Pipeline by Coherus BioSciences Inc, 142 Psoriasis – Pipeline by Compugen Ltd, 143 Psoriasis – Pipeline by Convoy Therapeutics Inc, 144 Psoriasis – Pipeline by Creabilis SA, 145 Psoriasis – Pipeline by Crescendo Biologics Ltd, 146 Psoriasis – Pipeline by Curapel Ltd, 147 Psoriasis – Pipeline by Cutanea Life Sciences Inc, 148 Psoriasis – Pipeline by Dermala Inc, 149 Psoriasis – Pipeline by Domainex Ltd, 150 Psoriasis – Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittle, 151 Psoriasis – Pipeline by EA Pharma Co Ltd, 152 Psoriasis – Pipeline by Eli Lilly and Company, 153 Psoriasis – Pipeline by ELORAC Inc, 154 Psoriasis – Pipeline by Exicure Inc, 155 Psoriasis – Pipeline by Foamix Pharmaceuticals Ltd, 156 Psoriasis – Pipeline by Forward Pharma A/S, 157 Psoriasis – Pipeline by Gem Pharmaceuticals LLC, 158 Psoriasis – Pipeline by Genentech Inc, 159 Psoriasis – Pipeline by Genor BioPharma Co Ltd, 160 Psoriasis – Pipeline by GlaxoSmithKline Plc, 161 Psoriasis – Pipeline by GlycoMar Ltd, 162 Psoriasis – Pipeline by Grupo Ferrer Internacional SA, 163 Psoriasis – Pipeline by HitGen LTD, 164 Psoriasis – Pipeline by Huabo Biopharm Co Ltd, 165 Psoriasis – Pipeline by Hydra Biosciences Inc, 166 Psoriasis – Pipeline by iCo Therapeutics Inc., 167 Psoriasis – Pipeline by Idera Pharmaceuticals Inc, 168 Psoriasis – Pipeline by Iltoo Pharma, 169 Psoriasis – Pipeline by Immune Pharmaceuticals Inc, 170 Psoriasis – Pipeline by Immune Response BioPharma Inc, 171 Psoriasis – Pipeline by Immungenetics AG, 172 Psoriasis – Pipeline by Innovent Biologics Inc, 173 Psoriasis – Pipeline by Jenrin Discovery Inc, 174 Psoriasis – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 175 Psoriasis – Pipeline by Johnson & Johnson, 176 Psoriasis – Pipeline by Kadmon Corp LLC, 177 Psoriasis – Pipeline by KaloBios Pharmaceuticals Inc, 178 Psoriasis – Pipeline by Kang Stem Biotech Co Ltd, 179 Psoriasis – Pipeline by KPI Therapeutics Inc, 180 Psoriasis – Pipeline by Lead Pharma Holding BV, 181 Psoriasis – Pipeline by Lee's Pharmaceutical Holdings Ltd, 182 Psoriasis – Pipeline by LEO Pharma A/S, 183 Psoriasis – Pipeline by Lipidor AB, 184 Psoriasis – Pipeline by Lupin Ltd, 185 Psoriasis – Pipeline by Lycera Corp, 186 Psoriasis – Pipeline by mAbxience SA, 187 Psoriasis – Pipeline by Maruho Co Ltd, 188 Psoriasis – Pipeline by Medestea Research & Production SpA, 189 Psoriasis – Pipeline by MediGene AG, 190 Psoriasis – Pipeline by Merck KGaA, 191 Psoriasis – Pipeline by MetrioPharm AG, 192 Psoriasis – Pipeline by Mitsubishi Tanabe Pharma Corp, 193 Psoriasis – Pipeline by Momenta Pharmaceuticals Inc, 194 Psoriasis – Pipeline by Mycenax Biotech Inc, 195 Psoriasis – Pipeline by NeuClone Pty Ltd, 196 Psoriasis – Pipeline by Nimbus Therapeutics LLC, 197 Psoriasis – Pipeline by NovaLead Pharma Pvt Ltd, 198 Psoriasis – Pipeline by Novan Inc, 199 Psoriasis – Pipeline by Novartis AG, 200 Psoriasis – Pipeline by Nuevolution AB, 201 Psoriasis – Pipeline by Numedii Inc, 202 Psoriasis – Pipeline by Oncobiologics Inc, 203 Psoriasis – Pipeline by OSE Immunotherapeutics, 204 Psoriasis – Pipeline by Panacea Biotec Ltd, 205 Psoriasis – Pipeline by Pfizer Inc, 206 Psoriasis – Pipeline by Pharis Biotec GmbH, 207 Psoriasis – Pipeline by Pharmedartis GmbH, 208 Psoriasis – Pipeline by Pieris Pharmaceuticals Inc, 209 Psoriasis – Pipeline by PinCell srl, 210 Psoriasis – Pipeline by Promius Pharma LLC, 211 Psoriasis – Pipeline by Protalix BioTherapeutics Inc, 212 Psoriasis – Pipeline by Prothena Corp Plc, 213 Psoriasis – Pipeline by Provectus Biopharmaceuticals Inc, 214 Psoriasis – Pipeline by RedHill Biopharma Ltd, 215 Psoriasis – Pipeline by Reliance Life Sciences Pvt Ltd, 216 Psoriasis – Pipeline by Samumed LLC, 217 Psoriasis – Pipeline by Sandoz International GmbH, 218 Psoriasis – Pipeline by Sareum Holdings Plc, 219 Psoriasis – Pipeline by Selvita SA, 220 Psoriasis – Pipeline by Shanghai Celgen Bio-Pharmaceutical Co Ltd, 221 Psoriasis – Pipeline by Shulov Innovative Science Ltd, 222 Psoriasis – Pipeline by Sigmoid Pharma Ltd, 223 Psoriasis – Pipeline by Soligenix Inc, 224 Psoriasis – Pipeline by Spherium Biomed SL, 225 Psoriasis – Pipeline by Stemline Therapeutics Inc, 226 Psoriasis – Pipeline by sterna biologicals Gmbh & Co KG, 227 Psoriasis – Pipeline by Sucampo Pharmaceuticals Inc, 228 Psoriasis – Pipeline by Sun Pharma Advanced Research Company Ltd, 229 Psoriasis – Pipeline by SWITCH Biotech LLC, 230 Psoriasis – Pipeline by Takeda Pharmaceutical Company Ltd, 231 Psoriasis – Pipeline by Tasly Pharmaceutical Group Co Ltd, 232 Psoriasis – Pipeline by Telormedix SA, 233 Psoriasis – Pipeline by Teva Pharmaceutical Industries Ltd, 234 Psoriasis – Pipeline by TheraMAB LLC, 235 Psoriasis – Pipeline by Therapix Biosciences Ltd, 236 Psoriasis – Pipeline by UCB SA, 237 Psoriasis – Pipeline by Valeant Pharmaceuticals International Inc, 238 Psoriasis – Pipeline by Vitae Pharmaceuticals Inc, 239 Psoriasis – Pipeline by Wellstat Therapeutics Corp, 240 Psoriasis – Pipeline by XBiotech Inc, 241 Psoriasis – Pipeline by XenoPort Inc, 242 Psoriasis – Pipeline by Yuhan Corp, 243 Psoriasis – Pipeline by Ziarco Pharma Ltd, 244 Atopic Dermatitis – Pipeline by AbbVie Inc, 245 Atopic Dermatitis – Pipeline by Abeome Corp, 246 Atopic Dermatitis – Pipeline by Accolade Pharmaceuticals LLC, 247 Atopic Dermatitis – Pipeline by Albireo Pharma Inc, 248 Atopic Dermatitis – Pipeline by Almirall SA, 249 Atopic Dermatitis – Pipeline by Amgen Inc, 250 Atopic Dermatitis – Pipeline by Amorepacific Corp, 251 Atopic Dermatitis – Pipeline by Anacor Pharmaceuticals Inc, 252 Atopic Dermatitis – Pipeline by AnaMar AB, 253 Atopic Dermatitis – Pipeline by AnaptysBio Inc, 254 Atopic Dermatitis – Pipeline by AnGes MG Inc, 255 Atopic Dermatitis – Pipeline by Avexxin AS, 256 Atopic Dermatitis – Pipeline by Blueberry Therapeutics Ltd, 257 Atopic Dermatitis – Pipeline by Brickell Biotech Inc, 258 Atopic Dermatitis – Pipeline by Celgene Corp, 259 Atopic Dermatitis – Pipeline by Cell Medica Ltd, 260 Atopic Dermatitis – Pipeline by Cellceutix Corp, 261 Atopic Dermatitis – Pipeline by ChemoCentryx Inc, 262 Atopic Dermatitis – Pipeline by ChironWells GmbH, 263 Atopic Dermatitis – Pipeline by Chugai Pharmaceutical Co Ltd, 264 Atopic Dermatitis – Pipeline by Clevexel Pharma SA, 265 Atopic Dermatitis – Pipeline by Creabilis SA, 266 Atopic Dermatitis – Pipeline by Curapel Ltd, 267 Atopic Dermatitis – Pipeline by Cutanea Life Sciences Inc, 268 Atopic Dermatitis – Pipeline by Dermala Inc, 269 Atopic Dermatitis – Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittle, 270 Atopic Dermatitis – Pipeline by Eli Lilly and Company, 271 Atopic Dermatitis – Pipeline by F. Hoffmann-La Roche Ltd, 272 Atopic Dermatitis – Pipeline by Foamix Pharmaceuticals Ltd, 273 Atopic Dermatitis – Pipeline by Fountain Biopharma Inc, 274 Atopic Dermatitis – Pipeline by Galapagos NV, 275 Atopic Dermatitis – Pipeline by GlaxoSmithKline Plc, 276 Atopic Dermatitis – Pipeline by Glenmark Pharmaceuticals Ltd, 277 Atopic Dermatitis – Pipeline by Grupo Ferrer Internacional SA, 278 Atopic Dermatitis – Pipeline by Han Wha Pharma Co Ltd, 279 Atopic Dermatitis – Pipeline by HanAll Biopharma Co Ltd, 280 Atopic Dermatitis – Pipeline by Heptares Therapeutics Ltd, 281 Atopic Dermatitis – Pipeline by Herantis Pharma Plc, 282 Atopic Dermatitis – Pipeline by iCo Therapeutics Inc., 283 Atopic Dermatitis – Pipeline by Immune Pharmaceuticals Inc, 284 Atopic Dermatitis – Pipeline by Inflamalps SA, 285 Atopic Dermatitis – Pipeline by Japan Tobacco Inc, 286 Atopic Dermatitis – Pipeline by Johnson & Johnson, 287 Atopic Dermatitis – Pipeline by Kang Stem Biotech Co Ltd, 288 Atopic Dermatitis – Pipeline by KPI Therapeutics Inc, 289 Atopic Dermatitis – Pipeline by LEO Pharma A/S, 290 Atopic Dermatitis – Pipeline by Madam Therapeutics BV, 291 Atopic Dermatitis – Pipeline by MedImmune LLC, 292 Atopic Dermatitis – Pipeline by Mitsubishi Tanabe Pharma Corp, 293 Atopic Dermatitis – Pipeline by NeoPharm Co Ltd, 294 Atopic Dermatitis – Pipeline by Novan Inc, 295 Atopic Dermatitis – Pipeline by Novartis AG, 296 Atopic Dermatitis – Pipeline by Orbis Biosciences Inc, 297 Atopic Dermatitis – Pipeline by Otsuka Holdings Co Ltd, 298 Atopic Dermatitis – Pipeline by Oxagen Ltd, 299 Atopic Dermatitis – Pipeline by Pfizer Inc, 300 Atopic Dermatitis – Pipeline by Pharis Biotec GmbH, 301 Atopic Dermatitis – Pipeline by Pharmedartis GmbH, 302 Atopic Dermatitis – Pipeline by Provectus Biopharmaceuticals Inc, 303 Atopic Dermatitis – Pipeline by PuriCore Plc, 304 Atopic Dermatitis – Pipeline by Regeneron Pharmaceuticals Inc, 305 Atopic Dermatitis – Pipeline by Roivant Sciences Ltd, 306 Atopic Dermatitis – Pipeline by Signum Dermalogix Inc, 307 Atopic Dermatitis – Pipeline by Spherium Biomed SL, 308 Atopic Dermatitis – Pipeline by sterna biologicals Gmbh & Co KG, 309 Atopic Dermatitis – Pipeline by Sucampo Pharmaceuticals Inc, 310 Atopic Dermatitis – Pipeline by Sun Pharma Advanced Research Company Ltd, 311 Atopic Dermatitis – Pipeline by SWITCH Biotech LLC, 312 Atopic Dermatitis – Pipeline by Takeda Pharmaceutical Company Ltd, 313 Atopic Dermatitis – Pipeline by Thesan Pharmaceuticals Inc, 314 Atopic Dermatitis – Pipeline by Torrent Pharmaceuticals Ltd, 315 Atopic Dermatitis – Pipeline by Trevi Therapeutics Inc, 316 Atopic Dermatitis – Pipeline by Valeant Pharmaceuticals International Inc, 317 Atopic Dermatitis – Pipeline by Vicore Pharma AB, 318 Atopic Dermatitis – Pipeline by Vitae Pharmaceuticals Inc, 319 Atopic Dermatitis – Pipeline by VivaCell Biotechnology Espana SL, 320 Atopic Dermatitis – Pipeline by Xencor Inc, 321 Atopic Dermatitis – Pipeline by Ziarco Pharma Ltd 322 Assessment by Monotherapy Products 323 Assessment by Combination Products 324 Number of Products by Stage and Target 326 Number of Products by Stage and Mechanism of Action 329 Number of Products by Stage and Route of Administration 332 Number of Products by Stage and Molecule Type 334 Assessment by Monotherapy Products 335 Assessment by Combination Products 336 Number of Products by Stage and Target 338 Number of Products by Stage and Mechanism of Action 348 Number of Products by Stage and Route of Administration 360 Number of Products by Stage and Molecule Type 362 Assessment by Monotherapy Products 363 Number of Products by Stage and Target 365 Number of Products by Stage and Mechanism of Action 369 Number of Products by Stage and Route of Administration 374 Number of Products by Stage and Molecule Type 376 Acne Vulgaris – Dormant Projects 377 Psoriasis – Dormant Projects 380 Atopic Dermatitis – Dormant Projects 389 Acne Vulgaris – Discontinued Products, 392 Psoriasis – Discontinued Products, 392 Atopic Dermatitis – Discontinued Products, 39 List of Figures Number of Products under Development for Acne Vulgaris, 16 Number of Products under Development for Acne Vulgaris – Comparative Analysis, 17 Number of Products under Development for Psoriasis, 18 Number of Products under Development for Psoriasis – Comparative Analysis, 19 Number of Products under Development for Atopic Dermatitis, 20 Number of Products under Development for Atopic Dermatitis – Comparative Analysis, 21 Number of Products under Development by Companies, 22 Number of Products under Development by Companies, 24 Number of Products under Development by Companies, 31 Number of Products under Investigation by Universities/Institutes, 34 Number of Products under Investigation by Universities/Institutes, 35 Number of Products under Investigation by Universities/Institutes, 36 Comparative Analysis by Late Stage Development, 37 Comparative Analysis by Clinical Stage Development, 38 Comparative Analysis by Early Stage Products, 39 Comparative Analysis by Late Stage Development, 40 Comparative Analysis by Clinical Stage Development, 41 Comparative Analysis by Early Stage Products, 42 Comparative Analysis by Late Stage Development, 44 Comparative Analysis by Clinical Stage Development, 45 Comparative Analysis by Early Stage Products, 46 Assessment by Monotherapy Products 323 Assessment by Combination Products 324 Number of Products by Top 10 Targets 325 Number of Products by Stage and Top 10 Targets 325 Number of Products by Top 10 Mechanism of Actions 328 Number of Products by Stage and Top 10 Mechanism of Actions 328 Number of Products by Routes of Administration 331 Number of Products by Stage and Routes of Administration 331 Number of Products by Molecule Types 333 Number of Products by Stage and Molecule Types 333 Assessment by Monotherapy Products 335 Assessment by Combination Products 336 Number of Products by Top 10 Targets 337 Number of Products by Stage and Top 10 Targets 337 Number of Products by Top 10 Mechanism of Actions 347 Number of Products by Stage and Top 10 Mechanism of Actions 347 Number of Products by Top 10 Routes of Administration 359 Number of Products by Stage and Top 10 Routes of Administration 359 Number of Products by Top 10 Molecule Types 361 Number of Products by Stage and Top 10 Molecule Types 361 Assessment by Monotherapy Products 363 Number of Products by Top 10 Targets 364 Number of Products by Stage and Top 10 Targets 364 Number of Products by Top 10 Mechanism of Actions 368 Number of Products by Stage and Top 10 Mechanism of Actions, 368 Number of Products by Top 10 Routes of Administration 373 Number of Products by Stage and Top 10 Routes of Administration, 373 Number of Products by Top 10 Molecule Types 375 Number of Products by Stage and Top 10 Molecule Types 375